Search

At the time of the first edition of Principles of Cancer Biotherapy in 1987, this book represented the first comprehensive textbook on biological therapy. In 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the therapeutic value of these new approaches. By 2003 and the fourth edition, it was generally agreed that biopharmaceuticals were producing major opportunities for new cancer therapies. Cancer biotherapy has now truly matured into the fourth modality of cancer treatment. This fifth revised edition describes the tremendous progress that has been made in recent years using biologicals in cancer treatment. This book summarizes an evolving science and a rapidly changing medical practice in biotherapy. In this new millennium, it is now possible to envision a much more diversified system of cancer research and treatment that will afford greater opportunities for a patient's personalized cancer treatment. This was first envisioned in the 1987 initial edition of this textbook and is now a'new'and popular approach to cancer treatment. Some forms of cancer biotherapy use the strategy of tumor stabilization and control though continued biological therapy, akin to the use of insulin in the treatment of diabetes. This textbook illustrates new methods of thinking and new strategies for control of cancer. It is always difficult to move from past dogma to future opportunity, but this fifth edition of Principles of Cancer Biotherapy illustrates why it is so important to the patients for researchers and clinicians to explore and quickly apply these new opportunities in cancer biotherapy.

Im ersten Teil des Buches werden Entwicklung, Aufbau und Systematik der Interferone sowie ihre Stellung innerhalb des Zytokin-Netzwerkes dargestellt. Weiterhin werden durch Interferone stimulierbare zytoplasmatische und nukleäre Veränderungen beschrieben. Der zweite Teil beschäftigt sich mit der klinischen Anwendung von Interferonen. Bei den wichtigsten malignen und benignen Krankheitsbildern werden die bisherigen Ergebnisse der Interferongabe dargestellt - auch in Kombination mit anderen systemischen und lokalen Behandlungsmaßnahmen - und mit herkömmlichen Behandlungsmethoden verglichen. Ziel des vorliegenden Buches ist es, möglichst umfassend und klar über Aufbau und Systematik des Interferonsystems sowie über seine bisherige klinische Bedeutung zu informieren.

At the time of the first edition of Principles of Cancer Biotherapy, this book represented the first comprehensive textbook on biological therapy. Whereas in 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the therapeutic value of these new approaches, it is now generally agreed that biopharmaceuticals are producing major opportunities for new cancer therapies. Cancer biotherapy has truly matured into the fourth modality of cancer treatment. The third edition is now needed as a result of the tremendous progress that has been made in recent years using biologicals in cancer treatment. The book summarizes an evolving science and a rapidly changing medical practice. As we near the millennium, it now becomes possible to envision a much more diversified system of cancer research and treatment that will afford greater opportunities for patients. Some forms of cancer biotherapy use the strategy of tumour stabilization and control through continued biological therapy, akin to the use of insulin in the treatment of diabetes. This textbook illustrates new methods of thinking and new strategies for control of cancer. It is always difficult to move from past dogma to future opportunity, but this third edition of Principles of Cancer Biotherapy illustrates why it is so important to the patients, for researchers and clinicians to explore and apply these new opportunities in cancer biotherapy.

This volume, Biological and Hormonal Therapies of Cancer, which is part of the series Cancer Treatment and Research, presents selected new information concerning biologic and hormonal therapy of cancer. We have attempted to provide the reader with topics of major interest in a timely fashion. There is renewed interest in biologic therapy of cancer. Two chapters review the role of interferon in the hematologic malignancies and in solid tumors. Vaccine therapies have come to the forefront of cancer therapy re­ cently, and two chapters approach different strategies of vaccine therapies; one reviews the cellular vaccine therapies and another the anti-idiotype ap­ proach. The hormonal therapy chapters focus on current uses of endocrine therapy in endometrial, breast, and prostate cancer. In addition, hormonal strategies for the prevention of breast cancer and endometrial cancer, including excit­ ing information relating to phytochemicals, are presented. The effects of tamoxifen on endometrium is a topic of major interest and is discussed in detail. Finally, there is a chapter on estrogen receptor expression and regula­ tion in human breast cancer. These chapters are all written by experts in the field and contain timely and relevant information of interest to laboratory and clinical scientists and practitioners alike. Biologic and endocrine therapies represent major areas of cancer research interest. The advent of newer biologic therapies, including new antibody­ targeted treatments, and the use of biologics as tumor modulators to enhance the effects of other treatment regimens is an exploding avenue of research.

The 7th volume of the book series Acute Leukemias provides new updates on the biology of acute leukemias and especially the underlying genetic and molecular events. High quality contributions are provided by leading scientists and clinicians making the book an excellent overview over most recent achievements which translate into new treatment strategies and hence an improved outlook for patients suffering from acute leukemias.